Study guide

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux

EBP-EAP Examination in Paediatrics Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding

EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)

2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity

Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections

Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

4 Chapter 4: Acute Paediatric Emergencies & Critical Care

EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination

5 Chapter 5: Paediatric Respiratory Medicine

Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

6 Chapter 6: Paediatric Cardiology

Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure

8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism

Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health

Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy

11 Chapter 11: Paediatric Haematology & Oncology

Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia

12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy

Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules

13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions

The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia

14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics

Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

15 Chapter 15: Paediatric Ophthalmology & ENT Disorders

Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions

16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health

Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance

17 Chapter 17: Adolescent Medicine & Healthcare Transition

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition

18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics

Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics

19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine

Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux

Key Takeaways Explain This Topic AI

Urinary tract infections in infants present with non-specific constitutional features (fever, irritability, poor feeding, faltering growth, prolonged jaundice), whereas older children manifest classic lower urinary tract signs (dysuria, frequency, urgency, secondary enuresis) or upper tract signs (loin pain, high pyrexia, rigors).

Prefer clean-catch urine; use a collection pad or catheterization/SPA when appropriate. Bag cultures are unreliable. A negative dipstick does not exclude UTI in infants under 3 months or high-risk presentations; these need microscopy/culture and prompt clinical assessment.

Diagnostic confirmation requires pure microbiological growth of ≥ 10 5 CFU/mL \ge 10^5\text{ CFU/mL} ≥ 1 0 5 CFU/mL of a single uropathogen from clean catch, ≥ 10 4 CFU/mL \ge 10^4\text{ CFU/mL} ≥ 1 0 4 CFU/mL from catheterization, or any growth from suprapubic aspiration; leukocyte esterase confirms pyuria, while nitrite provides high specificity for Gram-negative uropathogens.

Post-UTI imaging depends on age, recurrence and the guideline used. NICE uses selective ultrasound/DMSA/MCUG schedules; infants under 6 months with recurrent UTI need acute ultrasound. EAU uses broader febrile-UTI imaging. DMSA assesses cortical damage, while MCUG detects VUR and posterior urethral valves.

Last updated: November 2026

Paediatric Urinary Tract Infections and Vesicoureteral Reflux

Urinary tract infections (UTIs) represent one of the most common and clinically consequential bacterial infections in childhood, affecting approximately 2% of boys and 8% of girls by seven years of age. In infants and young children, acute pyelonephritis carries a distinct risk of permanent renal parenchymal scarring , which may predispose to long-term sequelae including hypertension, proteinuria, and chronic kidney disease (reflux nephropathy). Paediatricians must master the diagnostic nuances of sample collection, age-specific clinical manifestations, rational antibiotic stewardship, and risk-stratified radiological algorithms under European and international guidelines.

Pathogenesis and Microbiology

The vast majority of paediatric UTIs result from ascending infection , wherein enteric organisms colonize the periurethral mucosa and ascend retrogradely through the urethra into the bladder (cystitis) and potentially through the ureters into the renal pelvicalyceal system and parenchyma (acute pyelonephritis).

Primary Uropathogens

Uropathogenic Escherichia coli (UPEC) : Accounts for 75% to 90% of all community-acquired paediatric UTIs. UPEC strains possess specialized virulence factors:

P-fimbriae (pyelonephritis-associated pili) : Bind specifically to glycosphingolipid receptors on uroepithelial cells, facilitating ascension against urinary flow and adherence to renal tubular epithelium.

Type 1 fimbriae : Mediate attachment to mannosylated uroplakin proteins in the bladder epithelium.

Hemolysin and Cytotoxic Necrotizing Factor 1 (CNF-1) : Cause direct epithelial cytotoxicity and tissue invasion.

Other Enterobacteriaceae (10–15%) :

Klebsiella pneumoniae and Enterobacter species: Frequent in neonates, hospitalized infants, and children with anatomical anomalies.

Proteus mirabilis : Produces urease , which hydrolyzes urea into ammonia and carbon dioxide, raising urinary pH ( > 7.5 >7.5 > 7.5 ) and precipitating magnesium ammonium phosphate ( struvite stones ). Common in uncircumcised boys.

Citrobacter and Serratia species: Associated with instrumentation and broad-spectrum antibiotic exposure.

Gram-Positive Organisms (5%) :

Enterococcus faecalis : Encountered in neonates, children with neurogenic bladder, or structural uropathies.

Staphylococcus saprophyticus : Important cause of uncomplicated cystitis in sexually active adolescent females.

Group B Streptococcus (Streptococcus agalactiae) : Significant cause of early-onset neonatal sepsis and UTI.

Pseudomonas aeruginosa : Highly virulent opportunistic pathogen observed in children with neurogenic bladder, indwelling urinary catheters, or reconstructive urinary tract surgery.

Host Defense Mechanisms and Predisposing Factors

Under normal physiological conditions, the urinary tract is protected by:

Unidirectional, laminar urinary flow and periodic, complete bladder emptying.

Tamm-Horsfall glycoprotein (uromodulin) : Secreted by the thick ascending limb of Henle, binding to bacterial fimbriae and facilitating their clearance.

Uroepithelial secretion of antimicrobial peptides (defensins, cathelicidins) and secretory IgA.

Predisposing risk factors for paediatric UTI include:

Bladder and Bowel Dysfunction (BBD) : Chronic functional constipation with fecal impaction compresses the bladder neck, leading to incomplete voiding, urinary stasis, and high post-void residuals.

Uncircumcised Infant Males : In the first six months of life, uncircumcised boys have a four- to eight-fold higher risk of UTI compared to circumcised males due to dense colonization of the preputial space by uropathogens.

Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) : Posterior urethral valves (PUV), pelviureteric junction obstruction (PUJO), duplex collecting systems, and vesicoureteral reflux (VUR).

Neurogenic Bladder : Spina bifida / myelomeningocele resulting in detrusor-sphincter dyssynergia and elevated intravesical storage pressures.

Age-Stratified Clinical Manifestations

The clinical presentation of paediatric UTI varies inversely with the patient's age. The younger the infant, the more non-specific and constitutional the symptoms.

Age Bracket Characteristic Presentation Diagnostic Pitfalls

Neonates (<28 days) Temperature instability (fever or hypothermia), lethargy, poor feeding, faltering growth, vomiting, prolonged conjugated or unconjugated hyperbilirubinemia, grey skin mottling UTI frequently co-exists with or triggers systemic bacteremia; must form part of full neonatal septic workup

Infants (1 to 24 months) Unexplained pyrexia ( ≥ 38 ∘ C \ge 38^\circ\text{C} ≥ 3 8 ∘ C ), irritability, unexplained crying, feeding refusal, vomiting, foul-smelling urine, failure to thrive Often misattributed to viral upper respiratory infection, gastroenteritis, or teething

Preschool (2 to 5 years) Abdominal or suprapubic pain, dysuria, urinary frequency, new-onset secondary daytime or nighttime enuresis, foul-smelling urine Children may be unable to articulate dysuria; refusal to void or holding posturing may be misinterpreted as willful defiance

School-Age & Adolescents Cystitis : Dysuria, frequency, urgency, suprapubic ache; Pyelonephritis : High fever ( ≥ 38.5 ∘ C \ge 38.5^\circ\text{C} ≥ 38. 5 ∘ C ), rigors, costovertebral angle (loin) tenderness, nausea, vomiting Flank pain and fever in adolescent females require differentiation from pelvic inflammatory disease (PID), appendicitis, or nephrolithiasis

Note

Consider UTI in an infant with unexplained fever. Obtain a reliable urine sample before antibiotics where possible, but do not delay treatment in a seriously ill child if a sample cannot be obtained promptly.

Urine Collection Methodologies

Obtaining an uncontaminated urine specimen is the single most critical step in evaluating suspected paediatric UTI. Contamination with perineal, preputial, or fecal flora frequently leads to overdiagnosis, unnecessary hospitalizations, and redundant invasive imaging.

Non-Invasive Techniques

Clean-Catch (Midstream) Urine :

The preferred non-invasive technique in both toilet-trained children and cooperative infants.

Procedure in infants : The perineum is cleaned with sterile water. The infant is placed un-nappied on a caregiver's lap. The "Quick-Wee" method (gentle suprapubic cutaneous stimulation with cold-fluid-soaked gauze for 5-minute cycles) significantly accelerates voiding. The midstream flow is captured directly into a sterile container without contacting the skin.

Urine Collection Pads :

An absorbent pad is placed within a clean disposable nappy. The pad is inspected every 10 to 15 minutes. Once wet, urine is aspirated from the pad using a sterile syringe.

Acceptable alternative to clean catch, but carries a higher contamination risk if left in place prolonged or contaminated with stool.

Adhesive Perineal Collection Bags (Bag Urine) :

A plastic bag adhered to the perineum. Carries an unacceptably high false-positive culture rate of 50% to 70% due to skin commensals.

Interpretation : A positive bag culture cannot confirm UTI; obtain a reliable sample for culture. Negative dipstick screening lowers probability but does not exclude UTI in very young or high-risk infants. Treatment of serious illness must not wait for an unobtainable sample.

Invasive Techniques

Urethral Catheterization :

Indicated in acutely unwell, toxic, or hemodynamically unstable infants requiring immediate antimicrobial therapy when clean catch cannot be obtained promptly.

Performed using sterile technique with a 6-Fr or 8-Fr feeding tube/catheter.

Suprapubic Aspiration (SPA) :

The ultimate reference "gold standard" for obtaining pristine bladder urine in neonates and young infants.

Performed with a 21- to 23-gauge needle attached to a syringe, inserted 1 to 2 cm superior to the pubic symphysis in the midline at a 90-degree angle.

Bedside ultrasound guidance should always be utilized to confirm adequate bladder volume prior to puncture, increasing success rates to >90% and preventing dry taps or visceral injury. [Suspected Paediatric UTI]

  • |
  • [Reliable urine sample before antibiotics where possible]
  • [Do not delay urgent treatment if sampling is impractical]
  • |
  • +------------------------+------------------------+
  • | |
  • [Under 3 months or high-risk] [Age >=3 months, clinically stable]
  • [Upper UTI/serious illness] |
  • | [Clean catch; pad if needed]
  • [Urgent microscopy/culture] [Catheter/SPA if impractical]
  • [Paediatric assessment] |
  • | +--------------+---------------+
  • [Catheter/SPA if required] | |
  • [Positive dipstick] [Negative dipstick]
  • [Culture/treat by age] [UTI less likely]
  • [Culture if recurrent,
  • persistent or discordant]
  • Urinalysis and Diagnostic Thresholds

Rapid dipstick urinalysis guides initial care. Infants under 3 months require urgent microscopy/culture. At 3 months to under 3 years, either LE or nitrite positivity warrants culture and antibiotics. The table below applies from 3 years; culture despite a negative dipstick if upper UTI, serious illness, recurrence, persistence or clinical discordance is present.

Urinalysis Parameter Interpretation

Leukocyte Esterase (LE) :

Marker of pyuria. Detects esterase released from broken down or intact polymorphonuclear leukocytes.

Sensitivity: 80% to 90% ; Specificity: 70% to 85% .

False positives: Vaginal discharge, balanitis, extreme dehydration, kawasaki disease, interstitial nephritis.

False negatives: High specific gravity, glucosuria, presence of cephalosporins, or early infection.

Nitrite Test :

Detects the conversion of dietary nitrate into nitrite by bacterial nitrate reductase , an enzyme present in most Gram-negative enteric bacilli ( E. coli , Klebsiella , Proteus ).

Specificity: 98% (a positive test is virtually diagnostic of bacteriuria); Sensitivity: 45% to 60% .

Causes of False-Negative Nitrite :

Frequent infant voiding : Bacteria require at least 4 hours of bladder dwell time to convert nitrate into measurable quantities of nitrite. Infants who void hourly will frequently test nitrite-negative despite high-titer E. coli pyelonephritis.

Infection caused by non-nitrate-reducing organisms: Enterococcus faecalis , Pseudomonas aeruginosa , Staphylococcus saprophyticus , or Candida .

Low dietary intake of vegetables (nitrates).

  • Dipstick Finding Probability of UTI Clinical Action
  • LE positive, Nitrite positive High Presume UTI; send culture; initiate empiric antibiotic therapy
  • LE negative, Nitrite positive High Presume UTI; send culture; initiate empiric antibiotic therapy

LE positive, Nitrite negative Depends on clinical context Send culture; treat if there is convincing clinical evidence of UTI

LE negative, Nitrite negative Low when clinical risk is low Explore other causes; culture/reassess if high-risk or clinically discordant

Microbiological Diagnostic Criteria

Quantitative urine culture remains the definitive diagnostic gold standard. The diagnostic colony count threshold depends strictly on the collection method:

Clean-Catch Midstream Specimen : Pure growth of ≥ 10 5 colony-forming units (CFU)/mL \ge 10^5\text{ colony-forming units (CFU)/mL} ≥ 1 0 5 colony-forming units (CFU)/mL ( 10 8 CFU/L 10^8\text{ CFU/L} 1 0 8 CFU/L ) of a single uropathogen.

Urethral Catheterization : Pure growth of ≥ 10 4 CFU/mL \ge 10^4\text{ CFU/mL} ≥ 1 0 4 CFU/mL (or 10 4 – 10 5 CFU/mL 10^4\text{--}10^5\text{ CFU/mL} 1 0 4 – 1 0 5 CFU/mL in symptomatic patients).

Suprapubic Aspiration (SPA) : Any growth of a pathogenic organism is significant; interpret it with the clinical presentation and urinalysis.

Mixed Growth : The presence of two or more distinct bacterial organisms almost invariably represents perineal or fecal contamination and warrants re-sampling.

Evidence-Based Antimicrobial Therapy

Therapeutic decisions are guided by the clinical differentiation between upper UTI (acute pyelonephritis) and lower UTI (cystitis) , the child's age, and the presence of systemic toxicity.

Acute Pyelonephritis / Febrile UTI

Indications for Intravenous (IV) Therapy :

Neonates and infants younger than 2 to 3 months of age .

Toxic, septic, or hemodynamically compromised appearance.

Intractable vomiting, severe dehydration, or inability to retain oral medications.

Known severe renal tract anomaly, neurogenic bladder, or renal impairment.

Social concerns or uncertainty regarding treatment compliance.

Empiric Intravenous Regimens :

Infants ≥ 2 – 3 \ge 2\text{--}3 ≥ 2 – 3 months : IV Ceftriaxone (50 to 75 mg/kg once daily) or IV Cefotaxime (150 mg/kg/day divided 8-hourly).

Neonates (<2 months) : IV Ampicillin (to cover Enterococcus and Listeria ) plus IV Gentamicin (or Cefotaxime). When using gentamicin, therapeutic drug monitoring of peak and trough levels is mandatory to prevent nephrotoxicity and ototoxicity.

Alternative (penicillin allergy) : IV Ciprofloxacin or Aminoglycoside.

Oral Switch and Total Duration :

Transition to oral antibiotics is indicated once the child is clinically afebrile for 24 to 48 hours, feeding well, and antimicrobial sensitivities are confirmed.

Total antibiotic duration for acute pyelonephritis: 7 to 10 days (up to 14 days in neonates or complicated cases).

Uncomplicated Lower UTI (Cystitis) / Mild Febrile UTI

Children older than 2 to 3 months with mild symptoms, no systemic toxicity, and normal oral fluid intake can be treated entirely with oral antibiotics .

Empiric Oral Options :

Cefalexin : 50 mg/kg/day divided 8-hourly.

Amoxicillin-Clavulanic Acid (Co-amoxiclav) : 30 to 50 mg/kg/day divided 8-hourly.

Trimethoprim-Sulfamethoxazole (Co-trimoxazole) : 6 to 8 mg/kg/day of trimethoprim component divided 12-hourly.

Total Duration for Cystitis : 3 to 5 days .

Warning

Nitrofurantoin Contraindication in Pyelonephritis : Nitrofurantoin is excreted rapidly into the urine and achieves high, therapeutic concentrations within the lower urinary tract and bladder lumen. However, it achieves negligible therapeutic tissue concentrations in the renal parenchyma and bloodstream . Nitrofurantoin is therefore STRICTLY CONTRAINDICATED in acute pyelonephritis, febrile UTIs, and systemic urosepsis ; use it for lower UTI treatment or indicated prophylaxis, not for renal parenchymal infection or urosepsis.

Post-UTI Imaging: NICE and EAU Approaches

Radiological imaging post-UTI aims to identify treatable structural uropathies (such as posterior urethral valves), detect vesicoureteral reflux (VUR), and evaluate renal cortical scarring, while minimizing radiation exposure and procedural trauma.

Definitions of Complex UTI Subtypes

Atypical UTI : A UTI featuring any of the following:

  • Severe systemic illness, sepsis, or septic shock
  • Poor urine flow or abnormal urinary stream (suggestive of posterior urethral valves in boys)
  • Palpable abdominal, renal, or suprapubic mass
  • Raised serum creatinine or electrolyte disturbance

Failure to respond clinically (persistent fever or positive repeat culture) within 48 hours of starting appropriate antibiotics

Infection caused by a non-E. coli organism ( Proteus , Pseudomonas , Enterobacter , Klebsiella )

Recurrent UTI :

  • Two or more episodes of acute pyelonephritis / upper UTI, OR
  • One episode of upper UTI plus one or more episodes of lower UTI, OR

Three or more episodes of lower UTI / cystitis.

Core Imaging Modalities

Renal and Bladder Ultrasound (RBUS) :

Non-invasive, radiation-free evaluation of renal size, parenchymal thickness, pelvicalyceal dilatation, ureteric dilatation, bladder wall thickening, and post-void residual volume.

Acute RBUS under NICE : Indicated during atypical UTI and for recurrent UTI in infants under 6 months , to detect obstruction and other abnormalities. A responding non-E. coli infection with no other atypical feature may have ultrasound within 6 weeks.

Elective RBUS (within 6 weeks) : Indicated in infants younger than 6 months responding well to treatment for their first febrile UTI.

DMSA Scintigraphy ( 99 m Tc ^{99m}\text{Tc} 99 m Tc -Dimercaptosuccinic Acid) :

The diagnostic gold standard for evaluating renal parenchymal integrity and permanent cortical scarring .

Technetium-labeled DMSA is actively taken up by proximal convoluted tubular cells and fixed within the renal cortex.

Acute Phase : Reveals focal areas of photopenia (decreased uptake) representing acute parenchymal ischemia and inflammation (acute pyelonephritis).

Chronic Phase : Must be performed at least 4 to 6 months after the acute infection to allow post-inflammatory parenchymal healing. Persistent photopenic wedge defects with volume loss and cortical thinning define permanent renal scarring .

Micturating Cystourethrogram (MCUG / VCUG) :

The gold standard for detecting and grading Vesicoureteral Reflux (VUR) and visualizing the male urethra to diagnose Posterior Urethral Valves (PUV) .

Involves sterile urethral catheterization, instillation of radio-opaque contrast until maximum bladder filling, and continuous fluoroscopy during active voiding.

NICE indications : MCUG is recommended for atypical or recurrent UTI under 6 months ; consider it after an abnormal ultrasound. From 6 months to under 3 years , do not perform MCUG routinely, but consider it with dilatation, poor flow, non-E. coli infection or family history of VUR. It is not routine from age 3 years.

  • NICE clinical category Acute RBUS RBUS within 6 weeks DMSA at 4–6 months MCUG
  • First responding UTI (<6 mo) No Yes No Consider if ultrasound abnormal
  • First responding UTI (>=6 mo) No No No No
  • Atypical UTI (<6 mo) Yes No Yes Yes
  • Atypical UTI (6 mo–<3 yr) Yes No Yes Not routine; consider listed risk features
  • Atypical UTI (>=3 yr) Yes No No Not routine
  • Recurrent UTI (<6 mo) Yes No Yes Yes
  • Recurrent UTI (>=6 mo) No, unless otherwise indicated Yes Yes Not routine; consider listed features if <3 yr

For a responding non-E. coli infection without other atypical features, NICE permits ultrasound within 6 weeks rather than acutely. EAU differs : it recommends RBUS for febrile UTI, within 24 hours in infants/acutely ill children, with later imaging possible in stable outpatients. Consider VCUG after febrile UTI below 1 year, atypical/recurrent infection or abnormal ultrasound; consider DMSA at least 6 months after febrile UTI for scarring assessment.

Vesicoureteral Reflux (VUR)

Vesicoureteral reflux is the retrograde passage of urine from the bladder into the upper urinary tract through an incompetent ureterovesical junction (UVJ).

Pathophysiology

In healthy individuals, the ureter traverses the bladder wall obliquely through an intramural tunnel within the detrusor muscle before opening at the trigone. As the bladder fills and detrusor pressure rises, the intramural ureter is compressed against the bladder wall, creating a passive one-way flap-valve mechanism that prevents retrograde flow.

Primary VUR : Congenital shortening of the intramural ureteric tunnel (subnormal tunnel-to-diameter ratio, normally 5:1). Tendency toward spontaneous resolution as the child grows and the intramural tunnel elongates.

Secondary VUR : Elevated intravesical pressures that overcome a normal valve mechanism, resulting from posterior urethral valves, neurogenic bladder, or severe bladder-bowel dysfunction.

International Reflux Study Classification (Grades I to V) Grade I Grade II Grade III Grade IV Grade V

  • | | ( (( (((
  • | | ( ) (( )) ((( )))
  • | | ( ) (( )) ((( )))
  • | | | | | | | |
  • | | | | | | | |
  • | | / \ / \ ( )
  • | | / \ / \ ( )
  • Ureter Pelvis/ Mild dilation Moderate dilation Severe tortuosity
  • only calyces, & blunting of & tortuosity of & loss of papillary
  • no dilation fornices ureter impressions

Grade I : Reflux into non-dilated ureter only; does not reach the renal pelvis.

Grade II : Reflux reaches the renal pelvis and calyces without dilatation; calyceal fornices remain sharp and normal.

Grade III : Mild-to-moderate dilatation and tortuosity of the ureter and renal pelvis; mild blunting of calyceal fornices.

Grade IV : Moderate dilatation and tortuosity of the ureter and pelvis; complete blunting of calyces with preservation of papillary impressions.

Grade V : Severe dilatation and tortuosity of the ureter and renal pelvis; loss of calyceal papillary impressions; intrarenal reflux may be seen. Renal scarring is assessed separately.

Management Strategies for VUR

Conservative Medical Surveillance :

EAU estimates spontaneous resolution in nearly 80% of grades I–II and 30–50% of grades III–V within 4–5 years; bilateral high-grade reflux resolves less often.

Routine aggressive treatment of associated bladder-bowel dysfunction (BBD) with bowel laxatives (macrogol / polyethylene glycol), timed voiding (every 2–3 hours), and double voiding techniques.

Continuous Antibiotic Prophylaxis (CAP) :

Low-dose bedtime antibiotic (e.g., Trimethoprim 2 mg/kg nightly, or Nitrofurantoin 1–2 mg/kg nightly for infants > 3 >3 > 3 months).

Indicated primarily in infants with high-grade VUR (Grades IV and V) or children with recurrent febrile UTIs , to reduce recurrent febrile UTIs; prevention of new renal scarring has not been established.

Interventional Therapy (Endoscopic and Surgical) :

Indications : Breakthrough febrile UTIs despite CAP, persistent high-grade VUR (Grades IV–V) after 2 to 3 years of surveillance, or evidence of progressive new cortical scarring on DMSA.

Endoscopic Subureteric Transurethral Injection (STING) : Injection of a biocompatible bulking agent (dextranomer/hyaluronic acid copolymer, Deflux ) beneath the ureteric orifice to coapt the intramural lumen. Minimally invasive day-case procedure with > 80 % >80\% > 80% success.

Ureteric Reimplantation (Cohen Cross-Trigonal / Politano-Leadbetter) : Open or robotic-assisted surgical mobilization of the ureter with surgical reconstruction of an elongated intramural tunnel; definitive cure rate > 95 % >95\% > 95% .

Enuresis: Bedwetting and Daytime Wetting

Children are usually expected to be dry at night by a developmental age of about 5 years. Bedwetting is secondary if it starts after at least 6 months of dryness.

Tell the child and family that bedwetting is not the child's fault and that punishment must not be used.

Assess the pattern, daytime symptoms (frequency, urgency, daytime wetting, straining or a poor stream), fluid intake and toileting, and look for constipation, diabetes mellitus, urinary tract infection, developmental or emotional problems and family stress. Urinalysis is not routine but is needed if bedwetting is recent, if there are daytime symptoms or signs of illness, or if UTI or diabetes is suspected. Persistent secondary wetting without a medical explanation, or punishment for wetting despite advice, should raise concern about maltreatment.

First steps : adequate daytime drinks, avoiding caffeine, regular voiding during the day and before sleep, and rewards for agreed behaviours rather than for dry nights.

Enuresis alarm : first-line treatment for motivated families. Review at 4 weeks and continue until at least 2 weeks of uninterrupted dry nights.

Desmopressin : used when rapid or short-term dryness is the priority or an alarm is unsuitable, mainly from 7 years and considered from 5 years. Restrict fluid from 1 hour before until 8 hours after each dose because of the risk of water intoxication and hyponatraemia. Review at 4 weeks and continue for 3 months if responding. It is not used for daytime wetting alone.

Investigate and treat daytime symptoms first when they predominate, and refer when bedwetting does not respond to treatment or when bladder or neurological disease is suspected.

Source: NICE CG111 Bedwetting in under 19s .